Dynamic changes in the gut microbiota composition during adalimumab therapy in patients with ulcerative colitis: implications for treatment response prediction and therapeutic targets-Reference-Cited by-同舟云学术

Dynamic changes in the gut microbiota composition during adalimumab therapy in patients with ulcerative colitis: implications for treatment response prediction and therapeutic targets

Published:2024-08-26 Issue:1 Volume:16 Page:
ISSN:1757-4749
Container-title:Gut Pathogens
language:en
Short-container-title:Gut Pathog

Author:

Oh Han Na,Shin Seung Yong,Kim Jong-Hwa,Baek Jihye,Kim Hyo Jong,Lee Kang-Moon,Park Soo Jung,Kim Seok-Young,Choi Hyung-Kyoon,Kim Wonyong,Sul Woo Jun,Choi Chang Hwan

Funder

AbbVie and the National Research Foundation of Korea

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1186/s13099-024-00637-5.pdf

Reference43 articles.

1. Abegunde AT, Muhammad BH, Bhatti O, Ali T. Environmental risk factors for inflammatory bowel diseases: evidence based literature review. World J Gastroenterol. 2016;22(27):6296–317. https://doi.org/10.3748/wjg.v22.i27.6296.

2. Maaser C, Langholz E, Gordon H, Burisch J, Ellul P, Ramirez VH, et al. European Crohn’s and colitis organisation topical review on environmental factors in IBD. J Crohns Colitis. 2017;11(8):905–20. https://doi.org/10.1093/ecco-jcc/jjw223.

3. van der Sloot KWJ, Amini M, Peters V, Dijkstra G, Alizadeh BZ. Inflammatory bowel diseases: review of known environmental protective and risk factors involved. Inflamm Bowel Dis. 2017;23(9):1499–509. https://doi.org/10.1097/mib.0000000000001217.

4. Kaplan GG, Ng SC. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology. 2017;152(2):313-21.e2. https://doi.org/10.1053/j.gastro.2016.10.020.

5. Bernstein CN. Review article: changes in the epidemiology of inflammatory bowel disease-clues for aetiology. Aliment Pharmacol Ther. 2017;46(10):911–9. https://doi.org/10.1111/apt.14338.